항-PD-1 항체에 불응성인 NSCLC 환자의 치료

본 발명은 비-소세포 폐 암종(NSCLC)의 치료를 위해 증가된 치료 효능을 갖는 TIL의 치료 집단을 제조하기 위해 TIL을 제조하는 개선되고/개선되거나 단축된 과정 및 방법을 제공하고, 상기 NSCLC는 항-PD-1 항체에 의한 치료에 불응성이다. The present invention provides improved and/or shortened processes and methods for preparing TILs in order to prepare therapeutic populations of TILs with incr...

Full description

Saved in:
Bibliographic Details
Main Authors FARDIS MARIA, NATARAJAN ARVIND
Format Patent
LanguageKorean
Published 21.07.2021
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:본 발명은 비-소세포 폐 암종(NSCLC)의 치료를 위해 증가된 치료 효능을 갖는 TIL의 치료 집단을 제조하기 위해 TIL을 제조하는 개선되고/개선되거나 단축된 과정 및 방법을 제공하고, 상기 NSCLC는 항-PD-1 항체에 의한 치료에 불응성이다. The present invention provides improved and/or shortened processes and methods for preparing TILs in order to prepare therapeutic populations of TILs with increased therapeutic efficacy for the treatment of non-small cell lung carcinoma (NSCLC), wherein the NSCLC is refractory to treatment with an anti-PD-1 antibody.
Bibliography:Application Number: KR20217017216